| HOME >> BIOLOGY >> TECHNOLOGY |
control). The Company undertakes no obligation to publicly update forward- looking statements, whether because of new information, future events or otherwise, except as required by law.
RESPONSE GENETICS, INC.
CONSOLIDATED BALANCE SHEETS
As of As of
December June 30,
31, 2006 2007
(unaudited)
ASSETS
Current assets
Cash and cash equivalents $ 4,930,123 $ 19,427,868
Accounts receivable 1,288,255 2,229,921
Prepaid expenses and other current
assets 837,238 612,265
Total current assets 7,055,616 22,270,054
Property and equipment, net 1,184,963 2,422,049
Other assets 19,102 19,852
Total assets $ 8,259,681 $ 24,711,955
LIABILITIES AND STOCKHOLDERS'
(DEFICIT) EQUITY
Current liabilities
Accounts payable $ 404,008 $ 981,361
Accrued expenses 547,119 2,190,404
Accrued royalties 123,852 86,487
Accrued payroll, bonus and related
liabilities 595,276 178,023
Deferred revenue 1,628,325 3,753,763
Total current liabilities 3,298,580 7,190,038
Notes payable to stockholders 716,854 -
Accrued interest on notes payable
to stockholders 329,036 -
Accrued
'/>"/>
SOURCE Response Genetics, Inc. Copyright©2007 PR Newswire. |
Related biology technology :
1. Performance of Ad-A-Gene Cyclic AMP Response Element-Nitroreductase (CRE-NTR): an adenoviral vector gene delivery system
2. FLIPR Calcium 3 Assay Kit - An Optimal No-Wash Fluorescence Calcium Indicator Reagent for Non-Optimal Calcium Responses
3. IT critical in pandemic response, but many are not paying attention
4. Quick response manufacturing and biotech
5. Wisconsin court affirms damages in Innogenetics, Abbott patent case
6. Third Wave licenses Innogenetics tech to settle lawsuit
7. Symposium examines the effect of race on genetics and disease
8. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
9. Sonic Foundry reports GAAP loss as Q2 revenues rise
10. Fiserv reports $113.5 million in Q1 profit
11. Third Wave reports net loss of $18.9M for 2006
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |